X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES DR. REDDYS LAB ALKEM LABORATORIES/
DR. REDDYS LAB
 
P/E (TTM) x - 31.5 - View Chart
P/BV x 7.1 3.4 210.3% View Chart
Dividend Yield % 0.6 0.8 78.2%  

Financials

 ALKEM LABORATORIES   DR. REDDYS LAB
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
DR. REDDYS LAB
Mar-18
ALKEM LABORATORIES/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,5892,788 57.0%   
Low Rs1,2321,902 64.8%   
Sales per share (Unadj.) Rs417.5860.8 48.5%  
Earnings per share (Unadj.) Rs56.357.1 98.6%  
Cash flow per share (Unadj.) Rs64.7122.0 53.0%  
Dividends per share (Unadj.) Rs12.7020.00 63.5%  
Dividend yield (eoy) %0.90.9 105.6%  
Book value per share (Unadj.) Rs292.9757.7 38.7%  
Shares outstanding (eoy) m119.57165.91 72.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.7 124.0%   
Avg P/E ratio x25.141.1 61.0%  
P/CF ratio (eoy) x21.819.2 113.4%  
Price / Book Value ratio x4.83.1 155.6%  
Dividend payout %22.635.0 64.4%   
Avg Mkt Cap Rs m168,653389,034 43.4%   
No. of employees `000NA23.5 0.0%   
Total wages/salary Rs m9,17132,149 28.5%   
Avg. sales/employee Rs ThNM6,070.8-  
Avg. wages/employee Rs ThNM1,366.6-  
Avg. net profit/employee Rs ThNM402.5-  
INCOME DATA
Net Sales Rs m49,915142,810 35.0%  
Other income Rs m1,6451,552 106.0%   
Total revenues Rs m51,561144,362 35.7%   
Gross profit Rs m8,48223,512 36.1%  
Depreciation Rs m1,00610,772 9.3%   
Interest Rs m671788 85.1%   
Profit before tax Rs m8,45113,504 62.6%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6064,380 36.7%   
Profit after tax Rs m6,7319,468 71.1%  
Gross profit margin %17.016.5 103.2%  
Effective tax rate %19.032.4 58.6%   
Net profit margin %13.56.6 203.4%  
BALANCE SHEET DATA
Current assets Rs m27,062104,984 25.8%   
Current liabilities Rs m15,32468,938 22.2%   
Net working cap to sales %23.525.2 93.2%  
Current ratio x1.81.5 116.0%  
Inventory Days Days6774 89.4%  
Debtors Days Days41104 39.9%  
Net fixed assets Rs m12,610104,385 12.1%   
Share capital Rs m239830 28.8%   
"Free" reserves Rs m34,490124,886 27.6%   
Net worth Rs m35,027125,716 27.9%   
Long term debt Rs m1,21225,089 4.8%   
Total assets Rs m54,387225,443 24.1%  
Interest coverage x13.618.1 75.0%   
Debt to equity ratio x00.2 17.3%  
Sales to assets ratio x0.90.6 144.9%   
Return on assets %13.64.5 299.2%  
Return on equity %19.27.5 255.2%  
Return on capital %24.99.7 256.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56372,623 9.0%   
Fx outflow Rs m3,01218,916 15.9%   
Net fx Rs m3,55253,707 6.6%   
CASH FLOW
From Operations Rs m7,25918,030 40.3%  
From Investments Rs m1,864-14,883 -12.5%  
From Financial Activity Rs m-9,273-4,440 208.8%  
Net Cashflow Rs m-150-1,236 12.1%  

Share Holding

Indian Promoters % 66.9 25.5 262.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 5.4 613.0%  
FIIs % 0.0 35.3 -  
ADR/GDR % 0.0 18.5 -  
Free float % 0.0 15.3 -  
Shareholders   68,381 75,885 90.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PIRAMAL ENTERPRISES  NOVARTIS  PANACEA BIOTECH  MERCK LTD  GSK PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - SHASUN PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS